I Katona, TF Freund - Nat Med, 2008 - ipbl2.koki.hu Cannabis sativa is one of the oldest herbal plants in the history of medicine.
It was used in various therapeutic applications from pain to epilepsy, but its
psychotropic effect has reduced its usage in recent medical practice. ... Cited by 25 - Related articles - View as HTML - All 5 versions
V Di Marzo - Diabetologia, 2008 - Springer Abstract Endocannabinoids (ECs) are defined as endoge- nous agonists of
cannabinoid receptors type 1 and 2 (CB1 and CB2). ECs, EC anabolic and catabolic
enzymes and cannabinoid receptors constitute the EC signalling system. This ... Cited by 18 - Related articles - All 3 versions
A Astrup, S Madsbad, L Breum, TJ Jensen, JP … - The Lancet, 2008 - Elsevier We undertook a phase II, randomised, double-blind, placebo-controlled trial in
five Danish obesity management centres. After a 2 week run-in phase, 203 obese
patients (body-mass index 30−≤40 kg/m 2 ) were prescribed an energy ... Cited by 18 - Related articles - All 12 versions
AJ Scheen - Journal of neuroendocrinology, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 12 - Related articles - BL Direct - All 4 versions
V Micale, L Cristino, A Tamburella, S …, 2008 - nature.com The endocannabinoid-inactivating enzyme, fatty acid amide hydrolase (FAAH), and
the transient receptor potential vanilloid type-1 (TRPV1) channel are new
targets for the development of anxiolytic drugs. We studied the effect on ... Cited by 12 - Related articles - All 3 versions
- ►mayoclinicproceedings.com MJ Blaha, S Bansal, R Rouf, SH Golden, RS … - Mayo Clinic Proceedings, 2008 - mayoclinicproceedings.com The metabolic syndrome comprises a cluster of risk factors for cardiovascular
disease and type 2 diabetes mellitus that are due to abdominal obesity and
insulin resistance. This increasingly important proinflammatory condition ... Cited by 13 - Related articles - All 7 versions
JC Fruchart, F Sacks, MP Hermans, G … - The American Journal of Cardiology, 2008 - Elsevier Despite achieving targets for low-density lipoprotein (LDL) cholesterol, blood
pressure, and glycemia in accordance with current standards of care, patients
with dyslipidemia remain at high residual risk of vascular events. ... Cited by 13 - Related articles - All 7 versions
V Di Marzo, A Szallasi - British Journal of Pharmacology, 2008 - pubmedcentral.nih.gov The synthetic cannabinoid CB 1 receptor antagonist rimonabant (sold in the
United Kingdom under the brand name Acomplia) was reported to improve the
profile of cardiovascular risk factors in obese patients with the metabolic ... Cited by 9 - Related articles - All 4 versions
F Akbas, C Gasteyger, A Sjodin, A Astrup, TM … - Obes Rev, 2008 - interscience.wiley.com The discovery of cannabinoids, with the well-known stimulatory effect of
Cannabis sativa on appetite, has offered a new drug target for obesity
treatment. Cannabinoids act on two different receptors: CB1 receptors which ... Cited by 8 - Related articles - All 5 versions
V Di Marzo - Nat Clin Pract Cardiovasc Med, 2008 - canadiancpd.medscape.com Accumulation of large quantities of intra-abdominal visceral fat usually
accompanies overt obesity (BMI ≥30 kg/m 2 ), but is also found in overweight
individuals (BMI 25-29.9 kg/m 2 ). Visceral or intra-abdominal adiposity is ... Cited by 8 - Related articles - All 8 versions
